CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
SPM Activedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03347006
NCT03347006N/ACompleted

Exploratory Double Blind Placebo Controlled Study Investigating the Regulation of Proresolving Mediators and White Blood Cell Responses by Fish Oil Supplements in Healthy Volunteers

Queen Mary University of London·interventional·Posted Nov 20, 2017·Updated May 25, 2025

In Brief

A clinical study evaluating SPM Active for Healthy Volunteers. Completed, enrolled 22 participants across 1 site.

Detailed Summary

A randomised, double-blind, placebo-controlled study to determine whether fish oil supplementation regulates peripheral levels of specialized pro-resolving mediators and white blood cell responses in healthy volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
CollaboratorsMetagenics, Inc.

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 20, 2017
Enrollment StartMar 20, 2017
Primary CompletionJun 15, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.6 years ago

Interventions

SPM Activedietary

Supplement or placebo will be administered orally between 9 am to 9:30 am. * Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.